Corcept Therapeutics Incorporated is a Strong Buy after early FDA approval of Lyforli for PROC, with upside from EU decisions ...

One night in November 2018, I fell while crossing a street in Subic Bay, a U.S. naval logistics station in The Philippines. My face whacked the asphalt. Lying in the path of oncoming traffic, I couldn ...

- All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a biotechnology ...

Metagenomi is editing its pipeline, choosing to seek a partner for a program Moderna dropped and axing its amyotrophic lateral sclerosis (ALS) activities in response to setbacks at a competitor. The ...

Takeda Pharmaceuticals struck a deal with AcuraStem to purchase its amyotrophic lateral sclerosis (ALS) treatment program on Monday. Per terms of the transaction, the Japanese pharma giant will ...

VectorY Therapeutics has secured 129 million euros ($138 million) in a series A financing that will help the Dutch biotech advance its preclinical lead program in amyotrophic lateral sclerosis (ALS).

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 32nd International Symposium on ALS/MND ...

WASHINGTON — Veterans with the fatal disease ALS, along with their caregivers and advocates, warned lawmakers that the Department of Veterans Affairs delayed providing critical routine care, and the ...

LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...